JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200

Watchlist Manager
JiangSu WuZhong Pharmaceutical Development Co Ltd Logo
JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
Watchlist
Price: 9.48 CNY 1.5% Market Closed
Market Cap: 6.7B CNY
Have any thoughts about
JiangSu WuZhong Pharmaceutical Development Co Ltd?
Write Note

Income Statement

Earnings Waterfall
JiangSu WuZhong Pharmaceutical Development Co Ltd

Revenue
2.4B CNY
Cost of Revenue
-1.7B CNY
Gross Profit
669.1m CNY
Operating Expenses
-632.9m CNY
Operating Income
36.2m CNY
Other Expenses
-74m CNY
Net Income
-37.8m CNY

Income Statement
JiangSu WuZhong Pharmaceutical Development Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Revenue
Revenue
3 040
N/A
3 067
+1%
3 157
+3%
2 914
-8%
2 836
-3%
2 928
+3%
2 867
-2%
3 118
+9%
3 644
+17%
3 989
+9%
4 530
+14%
4 490
-1%
3 775
-16%
2 961
-22%
2 527
-15%
2 131
-16%
1 977
-7%
1 702
-14%
1 552
-9%
1 702
+10%
1 821
+7%
2 110
+16%
2 125
+1%
2 243
+6%
2 073
-8%
1 872
-10%
1 986
+6%
1 787
-10%
1 859
+4%
1 775
-4%
1 675
-6%
1 527
-9%
1 688
+11%
2 026
+20%
2 194
+8%
2 341
+7%
2 149
-8%
2 240
+4%
2 332
+4%
2 346
+1%
2 384
+2%
Gross Profit
Cost of Revenue
(2 557)
(2 615)
(2 698)
(2 510)
(2 444)
(2 594)
(2 578)
(2 820)
(3 332)
(3 555)
(4 073)
(3 973)
(3 171)
(2 323)
(1 845)
(1 445)
(1 339)
(1 099)
(1 011)
(1 142)
(1 240)
(1 487)
(1 521)
(1 682)
(1 527)
(1 300)
(1 440)
(1 232)
(1 320)
(1 270)
(1 157)
(1 018)
(1 165)
(1 448)
(1 624)
(1 740)
(1 577)
(1 698)
(1 809)
(1 774)
(1 715)
Gross Profit
483
N/A
452
-6%
459
+2%
404
-12%
393
-3%
335
-15%
289
-14%
298
+3%
312
+5%
434
+39%
457
+5%
517
+13%
603
+17%
637
+6%
682
+7%
686
+1%
639
-7%
603
-6%
541
-10%
559
+3%
581
+4%
623
+7%
605
-3%
561
-7%
546
-3%
572
+5%
546
-5%
555
+2%
539
-3%
505
-6%
518
+3%
509
-2%
523
+3%
578
+11%
570
-1%
601
+6%
572
-5%
542
-5%
522
-4%
572
+9%
669
+17%
Operating Income
Operating Expenses
(295)
(273)
(274)
(272)
(265)
(295)
(268)
(260)
(278)
(356)
(350)
(391)
(449)
(509)
(566)
(587)
(595)
(636)
(962)
(1 005)
(1 066)
(613)
(613)
(602)
(552)
(952)
(987)
(981)
(968)
(529)
(535)
(528)
(541)
(595)
(587)
(585)
(545)
(571)
(546)
(577)
(633)
Selling, General & Administrative
(286)
(250)
(268)
(269)
(263)
(264)
(272)
(267)
(286)
(318)
(348)
(394)
(436)
(452)
(557)
(576)
(596)
(584)
(571)
(604)
(668)
(615)
(605)
(593)
(544)
(623)
(617)
(608)
(599)
(514)
(522)
(519)
(521)
(559)
(567)
(562)
(519)
(515)
(517)
(545)
(608)
Research & Development
0
(5)
0
0
0
(7)
0
0
0
(16)
0
0
(10)
(41)
0
0
(6)
(51)
(47)
(52)
(47)
(12)
(11)
(15)
(17)
(37)
(38)
(38)
(42)
(19)
(27)
(25)
(25)
(27)
(30)
(30)
(34)
(37)
(40)
(43)
(43)
Depreciation & Amortization
0
(17)
0
0
0
(22)
0
0
0
(27)
0
0
0
(31)
0
0
0
(31)
0
0
0
(19)
0
0
0
(16)
0
0
0
(14)
0
0
0
(20)
0
0
0
(23)
0
0
0
Other Operating Expenses
(8)
(2)
(6)
(3)
(2)
(2)
4
7
8
4
(2)
3
(3)
15
(9)
(11)
7
29
(345)
(349)
(351)
34
3
7
9
(276)
(332)
(335)
(327)
18
14
16
6
11
9
7
8
4
11
11
18
Operating Income
189
N/A
179
-5%
185
+4%
132
-29%
128
-3%
40
-69%
20
-50%
37
+87%
34
-9%
78
+131%
107
+36%
126
+18%
154
+22%
128
-16%
116
-10%
100
-14%
44
-56%
(33)
N/A
(421)
-1 173%
(446)
-6%
(485)
-9%
10
N/A
(8)
N/A
(41)
-396%
(6)
+86%
(379)
-6 331%
(440)
-16%
(426)
+3%
(429)
-1%
(24)
+94%
(16)
+32%
(19)
-17%
(17)
+8%
(17)
+1%
(18)
-3%
16
N/A
28
+72%
(29)
N/A
(23)
+18%
(5)
+80%
36
N/A
Pre-Tax Income
Interest Income Expense
(54)
(62)
(59)
(31)
(33)
31
30
7
17
(39)
(35)
(23)
(18)
44
57
117
171
210
216
206
216
10
113
49
(19)
(43)
(51)
(52)
(54)
(45)
(47)
(46)
(50)
(58)
(37)
(45)
(45)
(64)
(73)
(68)
(71)
Non-Reccuring Items
0
0
0
0
0
0
0
0
0
(1)
(1)
(1)
(1)
2
0
(2)
(2)
(367)
0
0
0
81
(0)
(0)
0
(58)
100
100
100
105
(1)
(1)
(1)
0
0
2
2
20
(1)
(3)
(3)
Gain/Loss on Disposition of Assets
0
(0)
0
0
0
0
0
0
0
0
0
(0)
0
0
0
1
0
(1)
0
0
0
(1)
0
0
0
(2)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
13
17
16
17
14
14
15
19
15
10
7
4
10
8
6
(4)
(13)
(32)
(30)
(24)
(35)
(23)
(29)
(17)
(7)
(21)
(14)
(23)
(16)
3
0
(1)
(0)
(0)
(2)
(1)
(2)
1
2
2
1
Pre-Tax Income
147
N/A
133
-10%
142
+7%
117
-17%
108
-7%
85
-21%
66
-23%
63
-4%
66
+4%
48
-27%
78
+63%
106
+36%
144
+37%
184
+27%
179
-2%
212
+18%
201
-5%
(223)
N/A
(236)
-6%
(266)
-12%
(305)
-15%
77
N/A
76
-2%
(9)
N/A
(32)
-278%
(504)
-1 470%
(404)
+20%
(400)
+1%
(399)
+0%
39
N/A
(63)
N/A
(66)
-4%
(68)
-3%
(75)
-10%
(56)
+26%
(28)
+50%
(17)
+40%
(71)
-319%
(95)
-33%
(73)
+22%
(36)
+52%
Net Income
Tax Provision
(55)
(46)
(49)
(37)
(36)
(22)
(14)
(18)
31
30
28
25
(30)
(48)
(48)
(55)
(52)
(59)
(61)
(52)
(41)
(16)
(14)
(2)
(8)
(4)
(16)
(20)
(14)
(19)
(4)
(2)
(7)
(3)
(1)
(3)
(3)
(3)
(3)
(3)
(1)
Income from Continuing Operations
92
87
93
80
73
63
52
45
96
78
106
131
115
135
132
157
149
(282)
(297)
(318)
(346)
62
62
(10)
(40)
(508)
(420)
(420)
(413)
21
(67)
(68)
(76)
(78)
(58)
(31)
(20)
(74)
(97)
(76)
(37)
Income to Minority Interest
(47)
(46)
(58)
(38)
(34)
(14)
(7)
(9)
(7)
(6)
1
3
(2)
(2)
(3)
(5)
(3)
(3)
(2)
1
1
3
3
3
4
1
1
2
2
2
3
2
2
2
2
2
2
3
2
1
(1)
Net Income (Common)
45
N/A
41
-9%
34
-16%
42
+21%
39
-7%
49
+27%
45
-8%
36
-21%
89
+149%
72
-19%
107
+48%
134
+26%
113
-16%
133
+17%
129
-3%
152
+18%
147
-3%
(286)
N/A
(299)
-5%
(317)
-6%
(345)
-9%
65
N/A
65
+0%
(7)
N/A
(37)
-420%
(506)
-1 272%
(419)
+17%
(418)
+0%
(411)
+2%
23
N/A
(65)
N/A
(66)
-3%
(73)
-11%
(76)
-4%
(56)
+27%
(29)
+47%
(18)
+37%
(72)
-291%
(95)
-32%
(75)
+21%
(38)
+50%
EPS (Diluted)
0.08
N/A
0.07
-13%
0.06
-14%
0.07
+17%
0.07
N/A
0.07
N/A
0.08
+14%
0.06
-25%
0.13
+117%
0.11
-15%
0.16
+45%
0.2
+25%
0.17
-15%
0.18
+6%
0.18
N/A
0.21
+17%
0.2
-5%
-0.4
N/A
-0.42
-5%
-0.45
-7%
-0.49
-9%
0.09
N/A
0.08
-11%
-0.02
N/A
-0.06
-200%
-0.71
-1 083%
-0.58
+18%
-0.58
N/A
-0.56
+3%
0.03
N/A
-0.09
N/A
-0.1
-11%
-0.11
-10%
-0.11
N/A
-0.08
+27%
-0.04
+50%
-0.02
+50%
-0.1
-400%
-0.13
-30%
-0.11
+15%
-0.05
+55%

See Also

Discover More